拜耳先灵制药公司已完成了治疗子宫内膜异位症的新药Visanne在欧洲的审批程序。 Visanne是每日一次的口服片剂,含地诺孕素2毫克用于治疗子宫内膜异位症。 Visanne® - new long-term treatment for endometriosis submitted for registration in Europe In contrast to other drugs used for the treatment of this chronic gynecological disease, Visanneisanendometriosis-specific therapy for the longterm treatment of endometriosis. The current standard-therapy with GnRH analogue is only suitable for short-term treatment due to severe side-effects. “We focus on gynecological markets with significant growth potential where we aim for global leadership. With the submission of Visanne we have reached another important strategic milestone in thedevelopmentofinnovativegynecological products geared towards improving women’s health”, said Phil Smits, M.D., Head of Bayer Schering Pharma´s business unit Women’sHealthcare.“Asendometriosis is along-lastinggynecological condition that causes dramatic and recurrent pain, turning a woman’s life upside down, there is a need for an effective and well tolerated treatment that can be used over a long period of time. Visanne adresses this need with an endometriosis-specific therapy that has the same efficacy as the current therapeutic standard but with significantly less side effects, thus allowing for long-term treatment”, said Smits. The standard therapy GnRH analogue is only effective for the short-term relief of symptoms associated with endometriosis as safety concerns like decreased bone mineral density and hot flushes limit its long-term use. Further, both medical and surgical treatments are associated with high relapse rates which commonly result in the use of different combinations of the available treatment options and even repeat surgical procedures. Therefore, there is a need for new treatment options. Visanne’s efficacy and tolerability in treatment of endometrosis have been proven in several clinical studies. To date, more than 700 women have been treated with Visanne for up to 15 months. First data of the study results were presented at the annual meeting of the American Society for Reproductive Medicine (ASRM) in November 2008. Further data are planned for publication. About Endometriosis
Endometriosis is a common disease among women of reproductive age. The prevalence is estimated to be around 5-10% in women of childbearing age. Lower abdominal and pelvic pain, cramping menstrual pains (dysmenorrhea), painful sexual intercourse (dyspareunia) and infertility are well recognized symptoms of endometriosis. About Bayer
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at |